News & Updates

Show Multimedia Only

Soticlestat shows promise in rare, severe forms of childhood epilepsy

14 Aug 2022

The investigational drug soticlestat (TAK-935) helps reduce seizure frequency in children with Dravet syndrome (DS) or Lennox–Gastaut syndrome (LGS), with its safety profile consistent with previous data, according to the results of the phase II ELEKTRA trial.

14 Aug 2022

HCV reinfection highest among people with ongoing injecting drug use

14 Aug 2022

Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.

14 Aug 2022

Vincristine may disrupt long-term cardiac function in childhood cancer survivors

13 Aug 2022

In childhood cancer survivors (CCS), treatment with vincristine appears to be linked with global longitudinal strain (GLS) abnormalities over the long-term, a new study has found.

13 Aug 2022

Eosinophils confer protective benefit in acetaminophen-induced acute liver injury

12 Aug 2022

Hepatic recruitment of eosinophils appears to play a protective role during acute liver injury caused by acetaminophen overdose, reveals a recent study.

12 Aug 2022

Secukinumab 300 mg leads to sustained improvements in PsA symptoms

12 Aug 2022 by

Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.

12 Aug 2022

Another breakthrough for HIV: Fourth patient goes into long-term remission

12 Aug 2022 by

Hope springs yet again in the field of HIV treatment, as another HIV patient (reportedly the fourth in the world) goes into remission 3 decades following diagnosis. The patient stopped antiretroviral therapy (ART) after receiving allogeneic hematopoietic stem cell transplantation (HCT) of CCR5-Δ32/Δ32 donor cells for acute myelogenous leukaemia (AML).

12 Aug 2022

Relugolix-CT benefit for endometriosis-associated pain sustained through week 104

12 Aug 2022 by

Long-term combination therapy with relugolix plus oestradiol and norethindrone (relugolix-CT) shows sustained reductions in dysmenorrhoea and non-menstrual pelvic pain (NMPP) for up to 2 years in premenopausal women with endometriosis, according to the SPIRIT extension* study presented at ESHRE 2022.

12 Aug 2022

Ongoing canagliflozin treatment beneficial to diabetic patients with CKD

11 Aug 2022

Treatment with the sodium‐glucose cotransporter 2 inhibitor canagliflozin protects against cardiovascular events in patients with comorbid type 2 diabetes (T2D) and chronic kidney disease (CKD), with a larger absolute benefit for total cardiovascular than first cardiovascular events, according to a post hoc analysis.

11 Aug 2022

Teclistamab demonstrates clinical activity for R/R MM

11 Aug 2022 by

The T-cell-redirecting bispecific antibody teclistamab induced deep and durable responses in patients with triple-class-exposed relapsed or refractory multiple myeloma (R/R MM), findings from the phase I/II MajesTEC-1 trial have shown.

11 Aug 2022

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD

11 Aug 2022

In patients with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD), treatment with canagliflozin safely decreases the risk of developing end-stage renal disease, reports a new Japan study.

11 Aug 2022

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Soticlestat shows promise in rare, severe forms of childhood epilepsy

HCV reinfection highest among people with ongoing injecting drug use

Vincristine may disrupt long-term cardiac function in childhood cancer survivors

Eosinophils confer protective benefit in acetaminophen-induced acute liver injury

Secukinumab 300 mg leads to sustained improvements in PsA symptoms

Another breakthrough for HIV: Fourth patient goes into long-term remission

Relugolix-CT benefit for endometriosis-associated pain sustained through week 104

Ongoing canagliflozin treatment beneficial to diabetic patients with CKD

Teclistamab demonstrates clinical activity for R/R MM

Canagliflozin blunts end-stage renal disease risk in T2DM patients with CKD